ArticleHigh-throughput2018
Article in High-throughput, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Rewiring Drug Research and Development through Human Data-Driven Discovery (HDPharmaceutics · 2023Review
- Application of a patient-centered reverse translational systems-based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors.Clinical and translational science · 2022Article
- Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports.CPT: pharmacometrics & systems pharmacology · 2022Review
- A case study of a patient-centered reverse translational systems-based approach to understand adverse event profiles in drug development.Clinical and translational science · 2022Article
- No population left behind: Improving paediatric drug safety using informatics and systems biology.British journal of clinical pharmacology · 2022Review
- Detection of Short-Term Side Effects of ChAdOx1 nCoV-19 Vaccine: A Cross-Sectional Study in a War-Torn Country.Pragmatic and observational research · 2022Article
- Whole patient knowledge modeling of COVID-19 symptomatology reveals common molecular mechanisms.Frontiers in molecular medicine · 2022Article
- The COVID-19 explorer-An integrated, whole patient knowledge model of COVID-19 disease.Frontiers in molecular medicine · 2022Article
- Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting.Clinical pharmacology and therapeutics · 2021Article
- Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems.Drugs & therapy perspectives : for rational drug selection and use · 2021Article
- Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients.Cancers · 2020Article
- Radioimmunotherapy in Non-Hodgkin's Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar.Pharmaceuticals (Basel, Switzerland) · 2019Article
- Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data.Medicina (Kaunas, Lithuania) · 2019Article
- Adverse Event Circumstances and the Case of Drug Interactions.Healthcare (Basel, Switzerland) · 2019Article
- Examining Socioeconomic and Computational Aspects of Vaccine Pharmacovigilance.BioMed research international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a novel approach for the molecular transformation and analysis of patient clinical phenotypes. Building on the fact that drugs perturb the function of targets/genes, we integrated data from 8.2 million clinical reports detailing drug-induced side effects with the molecular world of drug-target information. Using this dataset, we extracted 1.8 million associations of clinical phenotypes to 770 human drug-targets. This collection is perhaps the largest phenotypic profiling reference of human targets to-date, and unique in that it enables rapid development of testable molecular hypotheses directly from human-specific information. We also present validation results demonstrating analytical utilities of the approach, including drug safety prediction, and the design of novel combination therapies. Challenging the long-standing notion that molecular perturbation studies cannot be performed in humans, our data allows researchers to capitalize on the vast tomes of clinical information available throughout the healthcare system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.